A phase IIIb, randomized, multicenter double-blind, placebo-controlled study of the immunogenicity and safety of two doses of GSK [GlaxoSmithKline] Biologicals' oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 weeks at the time of the first dose

Trial Profile

A phase IIIb, randomized, multicenter double-blind, placebo-controlled study of the immunogenicity and safety of two doses of GSK [GlaxoSmithKline] Biologicals' oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 weeks at the time of the first dose

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs RIX 4414 (Primary)
  • Indications Rotavirus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 11 Dec 2006 Status change
    • 25 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top